Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WHO Delists Panacea Biotec's Combination Vaccines From Pre-qualified List; Move Comes A Year After Action Against Sanofi's Shantha Unit

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In a stern signal intended to ensure product quality, the World Health Organization delisted combination vaccines made by Indian vaccine maker Panacea Biotec Ltd. from its list of pre-qualified suppliers

You may also be interested in...



India’s Expanding Vaccines Market Offers Promise To Global And Local Drug Firms (Part 2 of 2)

Several drug companies are gearing up to go full throttle into the Indian vaccines market with programs that go beyond pushing products and seek to build up public health awareness on a larger scale. GSK, Sanofi, Merck, Novartis and Pfizer are in the fray with local players Serum Institute of India, Bharat Biotech, and Panacea Biotec.

WHO Nod To India’s Regulatory System A Booster For Vaccine Makers

Indian vaccine makers see the latest move to qualify the Indian regulatory system as an opportunity to pump up exports.

India’s Vaccine Giant Serum Institute Sees Yearly Sales At $500 Million Until 2015 From Global Alliance Effort

India’s largest vaccines manufacturer will take a big chunk of the $4.3 billion public-private global commitment to enhance vaccines access set for June this year.

Related Content

UsernamePublicRestriction

Register

SC010771

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel